We are live on
!
Find out more
AI
Alphabet Inc Portfolio holdings
AUM
$4.02B
1-Year Est. Return
215.74%
This Fund
S&P 500
This Quarter
Est. Return
+51.28%
1 Year Est. Return
+215.74%
3 Year Est. Return
+350.01%
5 Year Est. Return
+242.03%
10 Year Est. Return
+998.87%
AUM
$2.14B
AUM Growth
+$558M
(+35%)
Cap. Flow
-$34.4M
Cap. Flow
% of AUM
-1.61%
Top 10 Holdings %
Top 10 Hldgs %
89.61%
Holding
40
New
–
Increased
–
Reduced
1
Closed
4
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CrowdStrike
CRWD
|
+$26.2M |
| 2 |
DM
Desktop Metal, Inc.
DM
|
+$5.42M |
| 3 |
KRON
Kronos Bio
KRON
|
+$1.19M |
| 4 |
VERV
Verve Therapeutics
VERV
|
+$1.03M |
| 5 |
Rani Therapeutics
RANI
|
+$565K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 55.72% |
| 2 | Healthcare | 35.16% |
| 3 | Industrials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
AST SpaceMobile
ASTS
$16.8B
| $418M | 19.57% |
8,943,486
| – | – |
|
2
Arm
ARM
$278B
| $317M | 14.85% |
1,960,784
| – | – |
|
3
Freshworks
FRSH
$2.84B
| $242M | 11.32% |
16,206,643
| – | – |
|
4
Planet Labs
PL
$7.3B
| $195M | 9.13% |
31,942,641
| – | – |
|
5
Revolution Medicines
RVMD
$40.2B
| $152M | 7.12% |
4,133,277
| – | – |
|
|
MTSR
6
DELISTED
Metsera Inc
MTSR
| $141M | 6.61% |
4,961,744
| – | – |
|
|
VERV
7
DELISTED
Verve Therapeutics
VERV
| $137M | 6.4% |
12,168,489
-180,597
| -1% | -$1.03M |
|
8
GitLab
GTLB
$5.28B
| $123M | 5.76% |
2,724,712
| – | – |
|
|
TEM
9
Tempus AI
TEM
$7.69B
| $98.6M | 4.62% |
1,551,102
| – | – |
|
10
DexCom
DXCM
$27.6B
| $90.5M | 4.24% |
1,036,937
| – | – |
|
11
UiPath
PATH
$5.62B
| $90M | 4.22% |
7,034,337
| – | – |
|
12
Prime Medicine
PRME
$533M
| $37.2M | 1.74% |
15,062,498
| – | – |
|
|
MAZE
13
Maze Therapeutics
MAZE
$1.53B
| $29.6M | 1.39% |
2,412,471
| – | – |
|
14
Oscar Health
OSCR
$8.5B
| $10.3M | 0.48% |
481,988
| – | – |
|
15
Sana Biotechnology
SANA
$885M
| $7.68M | 0.36% |
2,812,500
| – | – |
|
16
Monte Rosa Therapeutics
GLUE
$1.92B
| $6.6M | 0.31% |
1,464,015
| – | – |
|
17
Vera Therapeutics
VERA
$2.54B
| $5.68M | 0.27% |
241,264
| – | – |
|
18
Beam Therapeutics
BEAM
$2.58B
| $5.47M | 0.26% |
321,604
| – | – |
|
19
Relay Therapeutics
RLAY
$4.02B
| $5.43M | 0.25% |
1,568,753
| – | – |
|
20
Dianthus Therapeutics
DNTH
$5.68B
| $3.89M | 0.18% |
208,697
| – | – |
|
21
Lyell Immunopharma
LYEL
$309M
| $2.59M | 0.12% |
293,256
| – | – |
|
22
Spero Therapeutics
SPRO
$68.9M
| $2.58M | 0.12% |
889,979
| – | – |
|
23
Foghorn Therapeutics
FHTX
$285M
| $2.35M | 0.11% |
500,901
| – | – |
|
24
GeneDx Holdings
WGS
$1.75B
| $2.1M | 0.1% |
22,711
| – | – |
|
|
AUTL
25
Autolus Therapeutics
AUTL
$386M
| $1.59M | 0.07% |
698,262
| – | – |
|
Similar funds
JSW
BWA
MAM
GCM
USCWA
ICP
CA
MGP
Alphabet Inc's Q2 2025 Portfolio in Review
As of Q2 2025, Alphabet Inc held 40 positions worth $2.14B, up 35% from $1.58B the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Alphabet Inc's Q2 2025 filing shows 1 reduced and 4 closed positions. The largest sale was CrowdStrike, an estimated $26.2M.
By sector, the portfolio is most concentrated in Technology at 56% of assets, up from 55% a quarter earlier, followed by Healthcare and Industrials.
- Alphabet Inc's biggest Q2 2025 reduction was Verve Therapeutics, cutting an estimated $1.03M.
- Alphabet Inc fully exited CrowdStrike in Q2 2025, selling an estimated $26.2M.
- Alphabet Inc's ten largest holdings make up 90% of its $2.14B portfolio in Q2 2025.
- Alphabet Inc opened 0 new positions and closed 4 in Q2 2025.
- Alphabet Inc's portfolio value rose 35% quarter-over-quarter to $2.14B.
Based on Alphabet Inc's 13F filing for Q2 2025, filed 1 Aug 2025.